FTC’s over-focus on prices misses out on innovation, says pharma lawyer

The problem with antitrust in the pharmaceutical sector is that the Federal Trade Commission has an “obsessive focus” on price, Munger Tolles & Olson partner Rohit Singla has said.

Get unlimited access to all Global Competition Review content